These new findings have potentially important implications for clinical management of patients with serous OC.

Here we report the germline and somatic findings for two unrelated patients with NF1 and high-grade serous OC.

This study evaluates the association of afamin with survival and response to therapy in serous OC patients within the OVCAD consortium project.

All studies demonstrated that BRCA2-mutated patients are associated with better survival and therapeutic response than BRCA1-mutated and wild-type patients with serous OC.